ElectroCore, famous for bioelectronic medicines, is associating with UpScriptHealth to deliver its gammaCore treatment via direct-to-patient telemedicine program. This non-invasive stimulation therapy of vagus nerve is used to treat migraines and episodic cluster headaches among the adults.

GammaCore therapy was cleared in April 2017 to treat episodic cluster headaches, followed by FDA approval for migraines last January. The vagus nerve of the neck region is stimulated via a small electric current in a non-invasive nature, which is what makes the therapy different from other bioelectronics approaches.

Dan Duhart, the chief commercial officer of Dan Duhart said, “Through this program, we will enable patients to access a healthcare provider no matter where they are, and thereby expand access to people who may be suffering from migraines or episodic cluster headaches with a convenient therapy like gammaCore."

Patients are required to create an UpScript account, update the medical history followed by payment information. A telemedicine consultation with the provider will be scheduled by the patient. If gammaCore has to be prescribed, it will be shipped to the patient directly.

Peter Ax, the CEO of UpScriptHealth said, “When patients need care, they deserve to get it—easily, quickly and discreetly. The UpScript program offers patients a convenient option to access a healthcare provider and obtain the appropriate treatment.”

Only in last month, ElectroCore went public in a $78 million IPO.